Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

Benzinga Newsdesk www.benzinga.com Positive 59.1%

Neg 0% Neu 0% Pos 59.1%

Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.